What kind of kidney injury does Denosumab cause?

Electrolyte Disturbance — Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

How should kidney function be monitored during Denosumab therapy?

Serum calcium before every dose and within 1-2 weeks after, especially in CKD/dialysis; 25-OH vitamin D, magnesium, and phosphate; PTH in advanced CKD; ECG/QTc and symptoms if hypocalcemia is severe.

How can kidney injury from Denosumab be prevented?

Measure and correct serum calcium, vitamin D, and magnesium before dosing Co-prescribe calcium and active vitamin D (calcitriol), with higher doses in CKD Individualize the decision to dose in ESKD

Who is at higher risk of kidney injury from Denosumab?

Advanced CKD / dialysis (eGFR <30, and especially <15 mL/min/1.73 m2); Vitamin D deficiency and low baseline serum calcium; High bone-turnover states or extensive osteoblastic metastases (hungry-bone physiology); Hypomagnesemia impairing PTH action.

Back to explorer

Printable monograph

Anti-RANKL antibody

Denosumab

Xgeva · Dmab

Anti-RANKL antibody · approved 2010 · 10 citations

Up to date· through 2025

Fairly sourced6/9 · 5 signals

Met: 10 citations
Not met: 12+ references
Met: Accrued over 10+ years (span: 11y)
Met: Beyond single case reports
Not met: Peer-reviewed sources
Met: Landmark reference
Met: Current through 2025
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

An anti-RANKL antibody that is renally safe but can trigger dangerous hypocalcemia in low GFR.

ModerateAnti-RANKL monoclonal antibody

Bone metastases (skeletal-related events)Giant cell tumor of boneHypercalcemia of malignancy

§01

Signature kidney injury

Signature lesion

Electrolyte Disturbance

Representative incidence17%

Denosumab is not directly nephrotoxic and is not renally cleared, but the risk of severe hypocalcemia rises sharply as kidney function declines. In a population-based cohort, severe hypocalcemia occurred in 0.2% of all new users but in 14.9% of those with eGFR <15 mL/min/1.73 m2 or on dialysis (mild hypocalcemia 24.1% in that group). Reported rate: hypocalcemia in 17% — 850 patients with symptomatic newly diagnosed multiple myeloma and at least one lytic bone lesion who received at least… (Raje 2018, PMID 29429912).Source: Raje et al., Lancet Oncol 2018

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

Hypocalcemia appears within days to a few weeks of dosing with a nadir often around 1-2 weeks, and can be prolonged given the months-long effect and no reversal agent.

Distilled from: “Within days to a few weeks of dosing (nadir often around 1-2 weeks); can be prolonged given the drug's months-long duration of effect and the absence of a reversal agent.”

§02

Renal toxicities, ranked

This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Electrolyte Disturbance#1 · Signaturequalitative — no citable incidence
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

§03

Kidney injury

Mechanism of kidney injury

Profound inhibition of osteoclast-mediated bone resorption blocks the calcium efflux from bone needed to defend serum calcium. In advanced CKD, impaired 1-alpha-hydroxylation (low calcitriol), hyperphosphatemia, vitamin D deficiency, and reduced calcium mobilization compound the effect, producing severe and sometimes prolonged hypocalcemia with a compensatory surge in PTH. This is an electrolyte/mineral toxicity, not parenchymal kidney injury - renal function itself is not impaired by the drug.

Clinical presentation

Hypocalcemia with paresthesias, carpopedal spasm/tetany, Chvostek/Trousseau signs, QT prolongation, and seizures in severe cases, often with hyperphosphatemia and markedly elevated PTH. Renal function (creatinine/eGFR) is typically unchanged by the drug.

Management

Aggressive calcium and active vitamin D (calcitriol) repletion - oral and IV calcium for symptomatic/severe hypocalcemia; monitor and correct magnesium and phosphate; in dialysis patients adjust the calcium dialysate concentration. Hold further denosumab until calcium normalizes; effect persists for months, so prolonged supplementation may be needed.Lesion-level management framework

Risk factors

Advanced CKD / dialysis (eGFR <30, and especially <15 mL/min/1.73 m2)
Vitamin D deficiency and low baseline serum calcium
High bone-turnover states or extensive osteoblastic metastases (hungry-bone physiology)
Hypomagnesemia impairing PTH action

Prevention

Measure and correct serum calcium, vitamin D, and magnesium before dosing
Co-prescribe calcium and active vitamin D (calcitriol), with higher doses in CKD
Individualize the decision to dose in ESKD

Anticancer mechanism· how it treats cancer

Fully human monoclonal antibody against RANKL (receptor activator of nuclear factor-kappa-B ligand) that prevents RANKL from engaging its receptor RANK on osteoclast precursors, inhibiting osteoclast formation, function, and survival and thereby suppressing bone resorption. Used to prevent skeletal-related events in bone metastases, for giant cell tumor of bone, and for hypercalcemia of malignancy.

Note · Severe hypocalcemia in low GFR is the key hazard; denosumab is not directly nephrotoxic and is not renally cleared.

§04

Clinical depth

Renal dose adjustment

No dose reduction for renal function (cleared by the reticuloendothelial system, independent of GFR), but in CKD stage 4-5/dialysis the hazard is hypocalcemia - intensify calcium/vitamin D and monitoring rather than altering the dose. Avoid concurrent same-indication dosing of Xgeva and Prolia.

Dialyzability & ESKD dosing

Monoclonal antibody (IgG2); not dialyzable and pharmacokinetics are unaffected by dialysis. Hemodialysis is used to manage the metabolic consequences, not to remove the drug.

Differential diagnosis

Denosumab hypocalcemia (suppressed bone resorption, high PTH, recent dose) vs CKD-MBD hypocalcemia vs hungry-bone syndrome post-parathyroidectomy vs hypomagnesemia-related hypocalcemia. Note this is an electrolyte toxicity - the drug does not cause AKI, distinguishing it from nephrotoxic antiresorptives like IV bisphosphonates (which can cause ATN/collapsing FSGS).

Monitoring

Serum calcium before every dose and within 1-2 weeks after, especially in CKD/dialysis
25-OH vitamin D, magnesium, and phosphate
PTH in advanced CKD
ECG/QTc and symptoms if hypocalcemia is severe

Key trials & series

Cowan J Bone Miner Res 2023 ICES population-based cohort (hypocalcemia by eGFR)
Pivotal SRE-prevention trials in bone metastases (e.g. denosumab vs zoledronic acid programs)

Clinical pearls

Unlike bisphosphonates, denosumab is not nephrotoxic and needs no renal dose change - the danger in low GFR is hypocalcemia.
Check and replete calcium, vitamin D, and magnesium before dosing, and recheck calcium within 1-2 weeks in CKD/dialysis.
There is no reversal agent and the effect lasts months, so denosumab-induced hypocalcemia can be severe and prolonged - dialysis patients are highest risk.

Where it strikes· nephron segments & injury signatures

Nephron segments

Distal Tubule / Collecting Duct

Fine-tuning of Na, K, Mg, acid & water

Injury signatures

Electrolyte Disturbance

Beyond the kidney — non-renal toxicities· 1 organ systems

Class-level context for the major non-renal toxicities of the Anti-RANKL antibody class.

Musculoskeletal

Myalgia, myositis, rhabdomyolysis, ONJ

Osteonecrosis of the jaw, hypocalcemia, acute-phase reaction

§05

References

7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

7 references · 2018–2025 · 2 since 2023

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 3

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseB · ModerateRhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report.Neyra JA et al. · BMC Nephrol 2015 · PMID 26220655Biopsy-proven rhabdomyolysis-induced acute kidney injury with hyperkalemia, acidosis, and hypocalcemia after denosumab plus abiraterone, the first such reported renal adverse event.CaseC · LimitedSustained hypophosphatemia after denosumab in a patient on hemodialysis.Almodares AAS et al. · Bone 2024 · PMID 38341165Hemodialysis patient developed severe hypophosphatemia and hypocalcemia after denosumab, illustrating profound electrolyte wasting requiring IV phosphate in a kidney-failure setting.CaseC · LimitedSevere hypocalcemia after denosumab in a patient with acquired Fanconi syndrome.Shafqat H et al. · Osteoporos Int 2014 · PMID 24158473Acquired Fanconi syndrome patient suffered prolonged severe symptomatic hypocalcemia after a single denosumab dose, linking RANKL inhibition to electrolyte wasting in renal tubular dysfunction.

FDA label — boxed warning & renal dosing· renal impairment

Quoted verbatim from this agent's current FDA label (Aug 2026) — not paraphrased or interpreted. Full label on DailyMed .

Renal impairment — from the label

Two clinical trials were conducted in patients without cancer and with varying degrees of renal function. In one study, patients (N = 55) with varying degrees of renal function (ranging from normal through end-stage renal disease requiring dialysis) received a single 60 mg subcutaneous dose of denosumab. In a second study, patients (N = 32) with severe renal dysfunction (creatinine clearance less than 30 mL/min and/or on dialysis) were given two 120 mg subcutaneous doses of denosumab. In both studies, greater risk of developing hypocalcemia was observed with increasing renal impairment, and with inadequate/no calcium supplementation. Hypocalcemia was mild to moderate in severity in 96% of patients. Monitor calcium levels and calcium and vitamin D intake [see Warnings and Precautions ( 5.3 ), Adverse Reactions ( 6.1 ), and Clinical Pharmacology ( 12.3 )] .

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 201,380 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 3 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Electrolyte Disturbancecorroborated · ROR 2.95 — on the terms that name the lesion (ROR 2.17)

Electrolyte Disturbance

ROR 2.9595% CI 2.87–3.03· 5,221 reports

Hemorrhagic Cystitis

ROR 1.9495% CI 1.83–2.05· 1,273 reports

Crystal / Obstructive Nephropathy

ROR 1.3295% CI 1.22–1.42· 703 reports

FAERS outcomes & reporting trend· 12.8% of reports w/ death · 15.6% w/ hospitalization

12.8%

Reported with a death outcome

25,734 of 201,380 reports

15.6%

Reported with hospitalization

31,435 of 201,380 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 8 systems · 201,380 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 0.5195% CI 0.48–0.55· 755 AKI reports ·AKI is reported less often than for other drugs (CI entirely below 1) — no disproportionate signal.

Musculoskeletal

Arthralgia8,912Osteonecrosis Of Jaw8,645Pain In Extremity7,032Myalgia4,231Bone Pain4,043

General / constitutional

Fatigue7,747Pain6,963Back Pain6,930Fall5,228Asthenia4,084

Gastrointestinal

Nausea5,485Diarrhoea5,341Vomiting2,689

Skin

Rash4,342Pruritus2,992

Nervous system

Headache3,708Dizziness3,020

Respiratory

Dyspnoea3,753

Metabolic & electrolyte

Hypocalcaemia3,339

Immune / infection

Pneumonia2,745

Guidelines & consensus· 14

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

ASCO / CCORole of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline UpdateJ Clin Oncol 2017 · PMID 29035643Endorses denosumab 120 mg SC q4w, pamidronate 90 mg IV q3-4w, or zoledronic acid 4 mg IV q12w or q3-4w; nitrogen bisphosphonates require renal function monitoring and dose/interval adjustment for impaired clearance, whereas denosumab needs no renal dose adjustment (with hypocalcemia risk in CKD).

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Denosumab sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Necitumumab

Portrazza · Anti-EGFR antibody

Profile

Severe hypomagnesemia, class effect.

LYTE

Moderate#1 · 89% phenotype match

Inavolisib

Itovebi · PI3Kα inhibitor

Profile

PI3Kα inhibitor whose renal-relevant toxicity is on-target hyperglycemia and electrolyte shifts, not a kidney lesion.

LYTE

Moderate#2 · 86% phenotype match

Erdafitinib

Balversa · FGFR inhibitor

Profile

Hyperphosphatemia is an on-target class effect.

LYTE

Moderate#3 · 66% phenotype match

Futibatinib

Lytgobi · FGFR inhibitor

Profile

Hyperphosphatemia, class effect.

LYTE

Moderate#4 · 66% phenotype match

Pemigatinib

Pemazyre · FGFR inhibitor

Profile

Hyperphosphatemia; nephrocalcinosis risk.

LYTE

Moderate#5 · 66% phenotype match

Abiraterone

Zytiga · CYP17 inhibitor

Profile

Mineralocorticoid excess: hypokalemia, hypertension, edema.

LYTEHTN

Moderate#6 · 65% phenotype match

Compare Denosumab with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Bisphosphonates & bone

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

1IbandronateATN — Acute Tubular NecrosisMild
2Denosumab· this agentLYTE — Electrolyte DisturbanceModerate
3Zoledronic acidATN — Acute Tubular NecrosisFAERS AKIModerate
4PamidronateGLOM — Glomerular Injury / ProteinuriaSevere

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Denosumab’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Denosumab; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 126 clinical records among all 161 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.